SynteractHCR Team Participates In San Diego “Fight For Air” Climb Sponsored By The American Lung Association
SAN DIEGO--(BUSINESS WIRE)--A team from full-service, international contract research organization SynteractHCR, Inc. will participate in the American Lung Association’s “Fight for Air Climb” a stair-climbing challenge, to be held on Sunday, April 10, 2016 at 8:30 a.m. PDT. The CRO joins the fight against lung diseases in two ways: by participating in this event climbing a skyscraper; and through the many clinical research studies it conducts for drug developers working to find better drugs for diseases like asthma, cystic fibrosis, tuberculosis and lung cancer. The event brings together employees, friends and family members as both participants and donors.
“Our group has already raised more than our original goal of $1,000. We encourage anyone who would like to join the team or participate as a donor to access our page and join in the fun while also helping a worthy cause.”
The fundraiser is designed to help the more than 33 million people affected by lung disease in the U.S. This unique fitness challenge requires participants to climb up to the 32nd floor of One America Plaza. They can stop after one round of 657 steps or they can do a double climb of 1314 steps.
A mobile app has been developed for both iOS® and Android® platforms to help participants to fundraise using their smartphones and mobile tablets. SynteractHCR’s donation page and team roster can be found at the following link: http://action.lung.org/site/TR/Climb/ALACA_California?team_id=130199&pg=team&fr_id=13060
Team captain and Director of Clinical Operations for SynteractHCR Brooke Cobbs says, “Our group has already raised more than our original goal of $1,000. We encourage anyone who would like to join the team or participate as a donor to access our page and join in the fun while also helping a worthy cause.”
About SynteractHCR
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.